Petronilla Battista

Dr. Petronilla Battista

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
CSChristian Salvatore
Christian Salvatore
ACAntonio Cerasa
Antonio Cerasa
PBPetronilla Battista
Petronilla Battista
MGMaria C Gilardi
Maria C Gilardi
AQAldo Quattrone
Aldo Quattrone
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative
Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as to lessen the time and cost of clinical trials. Magnetic Resonance (MR)-related biomarkers have been recently identified by the use of machine learning methods for the in vivo differential diagnosis of AD. However, The vast majority of neuroimaging papers investigating this topic are focused on the difference between AD and patients with mild cognitive impairment (MCI), not considering the impact of MCI patients who will (MCIc) or not convert (MCInc) to AD. Morphological T1-weighted MRIs of 137 AD, 76 MCIc, 134 MCInc and 162 healthy controls (CN) selected from the Alzheimer’s disease neuroimaging initiative (ADNI) cohort, were used by an optimized machine learning algorithm. Voxels influencing the classification between these AD-related pre-clinical phases involved hippocampus, entorhinal cortex, basal ganglia, gyrus rectus, precuneus and cerebellum, all critical regions known to be strongly involved in the pathophysiological mechanisms of AD. Classification accuracy was 76% AD vs. CN, 72% MCIc vs. CN, 66% MCIc vs. MCInc (nested 20-fold cross validation). Our data encourage the application of computer-based diagnosis in clinical practice of AD opening new prospective in the early management of AD patients.

1 January 2017 in Behavioural Neurology
Verified
Journal Article
Open access
PDF file
PBPetronilla Battista
Petronilla Battista
CSChristian Salvatore
Christian Salvatore
ICIsabella Castiglioni
Isabella Castiglioni
Subjects with Alzheimer’s disease (AD) show loss of cognitive functions and change in behavioral and functional state affecting the quality of their daily life and that of their families and caregivers. A neuropsychological assessment plays a crucial role in detecting such changes from normal conditions. However, despite the existence of clinical measures that are used to classify and diagnose AD, a large amount of subjectivity continues to exist. Our aim was to assess the potential of machine learning in quantifying this process and optimizing or even reducing the amount of neuropsychological tests used to classify AD patients, also at an early stage of impairment. We investigated the role of twelve state-of-the-art neuropsychological tests in the automatic classification of subjects with none, mild, or severe impairment as measured by the clinical dementia rating (CDR). Data were obtained from the ADNI database. In the groups of measures used as features, we included measures of both cognitive domains and subdomains. Our findings show that some tests are more frequently best predictors for the automatic classification, namely, LM, ADAS-Cog, AVLT, and FAQ, with a major role of the ADAS-Cog measures of delayed and immediate memory and the FAQ measure of financial competency.

4 June 2017 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ECEleonora Catricala
Eleonora Catricala
EGElena Gobbi
Elena Gobbi
PBPetronilla Battista
Petronilla Battista
AMAntonio Miozzo
Antonio Miozzo
CPCristina Polito
Cristina Polito
PGPeter Garrard
Peter Garrard

9 November 2018 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
FPFrancesco Panza
Francesco Panza
Madia LozuponeMadia Lozupone
Madia Lozupone
RSRodolfo Sardone
Rodolfo Sardone
PBPetronilla Battista
Petronilla Battista
MPMarco Piccininni
Marco Piccininni
GLGiancarlo Logroscino
Giancarlo Logroscino
The peripheral hearing alterations and central auditory processing disorder (CAPD) associated with age-related hearing loss (ARHL), may impact cognitive disorders in older age. In older age, ARHL is also a significant marker for frailty, another age-related multidimensional clinical condition with a nonspecific state of vulnerability, reduced multisystem physiological reserve, and decreased resistance to different stressors (i.e. sensorial impairments, psychosocial stress, diseases, injuries). The multidimensional nature of frailty required an approach based on different pathogeneses because this clinical condition may include sensorial, physical, social, nutritional, cognitive, and psychological phenotypes. In the present narrative review, the cumulative epidemiological evidence coming from several longitudinal population-based studies, suggested convincing links between peripheral ARHL and incident cognitive decline and dementia. Moreover, a few longitudinal case-control and population-based studies also suggested that age-related CAPD in ARHL, may be central in determining an increased risk of incident cognitive decline, dementia, and Alzheimer’s disease (AD). Cumulative meta-analytic evidence confirmed cross-sectional and longitudinal association of both peripheral ARHL and age-related CAPD with different domains of cognitive functions, mild cognitive impairment, and dementia, while the association with dementia subtypes such as AD and vascular dementia remained unclear. However, ARHL may represent a modifiable condition and a possible target for secondary prevention of cognitive impairment in older age, social isolation, late-life depression, and frailty. Further research is required to determine whether broader hearing rehabilitative interventions including coordinated counseling and environmental accommodations could delay or halt cognitive and global decline in the oldest old with both ARHL and dementia.

1 July 2020 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
PBPetronilla Battista
Petronilla Battista
CSChristian Salvatore
Christian Salvatore
MBManuela Berlingeri
Manuela Berlingeri
ACAntonio Cerasa
Antonio Cerasa
ICIsabella Castiglioni
Isabella Castiglioni

25 March 2016 in Current Alzheimer Research
Verified
Journal Article
Closed access
CSChristian Salvatore
Christian Salvatore
PBPetronilla Battista
Petronilla Battista
ICIsabella Castiglioni
Isabella Castiglioni
The emergence of Alzheimer’s Disease (AD) as a consequence of increasing aging population makes urgent the availability of methods for the early and accurate diagnosis. Magnetic Resonance Imaging (MRI) could be used as in vivo, non invasive tool to identify sensitive and specific markers of very early AD progression. In recent years, multivariate pattern analysis (MVPA) and machine- learning algorithms have attracted strong interest within the neuroimaging community, as they allow automatic classification of imaging data with higher performance than univariate statistical analysis. An exhaustive search of PubMed, Web of Science and Medline records was performed in this work, in order to retrieve studies focused on the potential role of MRI in aiding the clinician in early diagnosis of AD by using Support Vector Machines (SVMs) as MVPA automated classification method. A total of 30 studies emerged, published from 2008 to date. This review aims to give a state-of-the-art overview about SVM for the early and differential diagnosis of AD-related pathologies by means of MRI data, starting from preliminary steps such as image pre-processing, feature extraction and feature selection, and ending with classification, validation strategies and extraction of MRI-related biomarkers. The main advantages and drawbacks of the different techniques were explored. Results obtained by the reviewed studies were reported in terms of classification performance and biomarker outcomes, in order to shed light on the parameters that accompany normal and pathological aging. Unresolved issues and possible future directions were finally pointed out.